Ischemic Stroke, Stroke
Conditions
Brief summary
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.
Interventions
OTHERImmuno-inflammatory profile description in patients with ischemic stroke
Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
All patients undergoing a reperfusion procedure as part of an ischemia stroke will be able to participate in the study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years of age * Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both) * Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent) * Affiliated with or beneficiary of a social security system
Exclusion criteria
* Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI) * Intracranial hemorrhage associated with AIC on initial imaging Immunosuppressive treatment or corticosteroid therapy at patient admission * Pre-existing neurological disability limiting neurological assessment at 3 months (mRS\>2 at admission) * Known and diagnosed dementia pre-existing at the time of the AIC * Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \<15mL/min, pregnant or breastfeeding women) * Patient treated by another institution and referred solely for mechanical thrombectomy * Patient benefiting from legal protection measures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment | Up to year | Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA preconfigurated panels for inflammatory biomarkers. |
Contacts
CONTACTBenjamin MAIER, Professor, MD, PhD
CONTACTAmélie YAVCHITZ, MD, PhD
Outcome results
None listed